Morgan Stanley analyst Terence Flynn has maintained their neutral stance on PRME stock, giving a Hold rating today. Terence Flynn’s ...
On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...
Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...
5don MSN
We recently compiled a list of the 8 Dividend Giants with Lowest Short Interest in 2024. In this article, we are going to ...
The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition. Karuna’s crown jewel, an ...
PRINCETON, N.J., September 27, 2024--U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults Business Wire • 6 hours ...
We recently compiled a list of the 10 Best Beaten Down Dividend Stocks to Invest in Now. In this article, we are going to ...
Stock futures dipped early Friday morning as investors geared up to closely monitor new personal spending and inflation data. These economic indicators could offer insights into the health of the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback